C5orf34_4833420G17Rik Inhibitors
Chemical inhibitors of C5orf34 function primarily through the interruption of signal transduction pathways that are crucial for its activity. Erlotinib, by targeting the epidermal growth factor receptor (EGFR), can hinder downstream signaling mechanisms that C5orf34 may rely on in cellular contexts where EGFR plays a pivotal role. Similarly, lapatinib and afatinib disrupt the signaling by inhibiting EGFR, as well as HER2/neu tyrosine kinase domains, which are likely involved in the pathways regulating C5orf34 activity. Sorafenib and pazopanib, with their multi-kinase inhibition profile, can interfere with various signaling cascades by targeting RAF kinase, VEGFR, and PDGFR, possibly affecting C5orf34 function when these pathways are upstream regulators. Sunitinib, which also inhibits VEGFR and PDGFR, alongside other kinases, can block the signaling routes that control C5orf34.
Dasatinib and nilotinib specifically target the Bcr-Abl tyrosine kinase and Src family kinases, which can suppress the signaling networks that might be crucial for the functional regulation of C5orf34, especially in scenarios where Bcr-Abl is a significant regulator. Vandetanib's selective inhibition of RET-tyrosine kinase, VEGFR, and EGFR signaling pathways can also result in a reduction of C5orf34 activity. Imatinib, by inhibiting Bcr-Abl tyrosine kinase, c-Kit, and PDGFR, can lead to the inhibition of signaling pathways involved in the regulation of C5orf34. Crizotinib and axitinib offer a different approach by inhibiting ALK and MET tyrosine kinases, and VEGFR tyrosine kinases respectively, which can alter the signaling pathways that C5orf34 is part of and lead to its functional inhibition. These chemicals collectively demonstrate a range of mechanisms by which the activity of C5orf34 can be inhibited, each targeting different kinases and receptors that are potentially involved in the signaling pathways that regulate C5orf34.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which can lead to a decrease in downstream signaling pathways that may be necessary for the activity of C5orf34 in cells where EGFR signaling contributes to its function. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases including RAF kinase, VEGFR, and PDGFR. Inhibition of these kinases can disrupt the signaling cascades that are essential for the function of C5orf34, particularly in cellular contexts where these pathways are upstream regulators. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor, known to block cellular signaling by targeting PDGFR, VEGFR, and other kinases. This blockade can inhibit the signaling pathways that regulate the activity of C5orf34. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits several tyrosine kinases including Bcr-Abl and Src family kinases. By inhibiting these kinases, Dasatinib can suppress the signaling networks that might be crucial for the functional regulation of C5orf34. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-kit. Inhibition of these receptors can lead to the disruption of signaling pathways that control the activity of C5orf34. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib specifically inhibits Bcr-Abl tyrosine kinase, as well as other tyrosine kinases like c-Kit and PDGFR. This can lead to the inhibition of signaling cascades involved in regulating the function of C5orf34. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib inhibits the tyrosine kinase domains in both EGFR and HER2/neu which are involved in key signaling pathways. Inhibition of these pathways is likely to downregulate the activity of C5orf34 through decreased activation of these pathways. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib is a selective Bcr-Abl tyrosine kinase inhibitor that can inhibit signaling pathways required for C5orf34 activity, particularly in cells where Bcr-Abl is a key regulator of those pathways. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib selectively inhibits RET-tyrosine kinase, VEGFR, and EGFR signaling pathways which could be integral to C5orf34 activity. Inhibition of these pathways can lead to a reduction in C5orf34 activity. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $114.00 $198.00 | 13 | |
Afatinib irreversibly inhibits EGFR and HER2 which are involved in key cell signaling pathways. The disruption of these pathways can lead to the inhibition of functions regulated by C5orf34. | ||||||